Table 1. Baseline characteristics of the lung cancer patients with ALK rearrangement.
| Characteristic | Patients, n (%) | Sequential therapy group, n (%) | Direct second-generation group, n (%) | P value |
|---|---|---|---|---|
| Age, years | 0.249 | |||
| Mean (standard deviation) | 53.4 (10.25) | 52.5 (9.9) | 54.6 (10.6) | |
| Median | 54.0 | 54.0 | 55.5 | |
| Range | 28–81 | 28–80 | 30–81 | |
| Sex | >0.999 | |||
| Male | 99 (46.9) | 54 (47.0) | 45 (46.9) | |
| Female | 112 (53.1) | 61 (53.0) | 51 (53.1) | |
| ECOG PS | 0.526 | |||
| 0 or 1 | 186 (88.2) | 103 (89.6) | 83 (86.5) | |
| 2 | 25 (11.8) | 12 (10.4) | 13 (13.5) | |
| Smoking history | 0.102 | |||
| Yes | 146 (69.2) | 74 (64.3) | 72 (75.0) | |
| No | 65 (30.8) | 41 (35.7) | 24 (25.0) | |
| Current stage of disease | 0.483 | |||
| IIIB-IIIC | 16 (7.6) | 7 (6.1) | 9 (9.4) | |
| IV | 195 (92.4) | 108 (93.9) | 87 (90.6) | |
| Histologic type | 0.416 | |||
| Adenocarcinoma | 204 (96.7) | 113 (98.3) | 91 (94.8) | |
| Squamous cell carcinoma | 4 (1.9) | 1 (0.9) | 3 (3.1) | |
| Other | 3 (1.4) | 1 (0.9) | 2 (2.1) | |
| ALK test method | 0.093 | |||
| FISH | 7 (3.3) | 4 (3.5) | 3 (3.1) | |
| Reverse transcriptase PCR | 24 (11.4) | 16 (13.9) | 8 (8.3) | |
| Ventana IHC | 102 (48.3) | 61 (53.0) | 41 (42.7) | |
| NGS | 78 (37.0) | 34 (29.6) | 44 (45.8) | |
| Brain metastasis | 0.752 | |||
| Yes | 54 (25.6) | 28 (24.3) | 26 (27.1) | |
| No | 157 (74.4) | 87 (75.7) | 70 (72.9) | |
| Bone metastasis | 0.445 | |||
| Yes | 60 (28.4) | 30 (26.1) | 30 (31.3) | |
| No | 151 (71.6) | 85 (73.9) | 66 (68.8) | |
| Liver metastasis | >0.999 | |||
| Yes | 38 (18.0) | 21 (18.3) | 17 (17.7) | |
| No | 173 (82.0) | 94 (81.7) | 79 (82.3) | |
| Previous surgery | 0.411 | |||
| Yes | 48 (22.7) | 29 (25.2) | 19 (19.8) | |
| No | 163 (77.3) | 86 (74.8) | 77 (80.2) | |
| Previous radiotherapy | 0.386 | |||
| Yes | 41 (19.4) | 25 (21.7) | 16 (16.7) | |
| No | 170 (80.6) | 90 (87.3) | 80 (83.3) | |
| Previous chemotherapy | 0.056 | |||
| Yes | 70 (33.2) | 45 (39.1) | 25 (26.0) | |
| No | 141 (66.8) | 70 (60.9) | 71 (74.0) |
ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group Performance status; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing; PCR, polymerase chain reaction.